Klein Laura Cousino, Whetzel Courtney A, Bennett Jeanette M, Ritter Frank E, Nater Urs M, Schoelles Michael
Department of Biobehavioral Health & Penn State Institute of the Neurosciences, The Pennsylvania State University, 219 Biobehavioral Health Building, University Park, PA 16802, USA.
BMC Res Notes. 2014 Jan 13;7:30. doi: 10.1186/1756-0500-7-30.
To follow up on a recent report from our lab [Hum Psychopharmacol 25:359-367, 2010.] we examined the effects of caffeine on salivary α-amylase (sAA) activity in response to an engaging, non-stressful task in healthy young males (age 18-30 yrs) who consumed caffeine on a daily basis. Using a placebo-controlled, double-blind, between-subjects design, 45 men received either placebo, 200 mg or 400 mg of caffeine (Vivarin®). Participants then rested for 20 minutes, and performed a 20-minute computerized air traffic controller-like task that was cognitively engaging but not stressful. Saliva samples (assayed for sAA and cortisol), blood pressure, and heart rate were taken before (baseline) and 15 minutes after the computerized task.
Systolic and diastolic blood pressure and sAA activity increased across the laboratory session (F's > 9.20, p's < 0.05); salivary cortisol levels decreased (F = 16.17, p < 0.05). There were no main effects for caffeine administration on sAA, salivary cortisol, or cardiovascular measures, and caffeine did not interact with the task to alter these measures.
Laboratory administered caffeine does not alter sAA activity, even when sAA activity is stimulated by participating in a cognitively engaging task. These data demonstrate that caffeine administration does not affect sAA activity, at least in healthy young men who regularly consume caffeine. Results support recent findings that basal caffeine levels in habitual caffeine users are not associated with basal sAA activity and that daily caffeine intake and diurnal sAA activity are not related.
为跟进我们实验室最近的一份报告[《人类精神药理学》25:359 - 367, 2010年],我们研究了咖啡因对健康年轻男性(年龄18 - 30岁,每日饮用咖啡因)在参与一项引人入胜、无压力任务时唾液α - 淀粉酶(sAA)活性的影响。采用安慰剂对照、双盲、组间设计,45名男性分别接受安慰剂、200毫克或400毫克咖啡因(维瓦林®)。参与者随后休息20分钟,然后进行一项20分钟的类似空中交通管制员的计算机任务,该任务具有认知挑战性但无压力。在计算机任务前(基线)和任务后15分钟采集唾液样本(检测sAA和皮质醇)、血压和心率。
整个实验过程中收缩压和舒张压以及sAA活性均升高(F值> 9.20,p值< 0.05);唾液皮质醇水平下降(F = 16.17,p < 0.05)。咖啡因给药对sAA、唾液皮质醇或心血管指标无主效应,且咖啡因与任务之间未相互作用以改变这些指标。
实验室给予的咖啡因不会改变sAA活性,即使sAA活性因参与认知挑战性任务而受到刺激。这些数据表明,至少在经常饮用咖啡因的健康年轻男性中咖啡因给药不影响sAA活性。结果支持了最近的研究发现,即习惯性咖啡因使用者的基础咖啡因水平与基础sAA活性无关,且每日咖啡因摄入量与昼夜sAA活性无关。